Earnings recap · AMGN
Amgen Q3 2026 results
What Amgen reported for Jul to Sep 2026, compared with the same quarter a year earlier, from the press release it filed with the SEC.
10-Q filed Amgen filed its quarterly report for this quarter on Nov 4, 2026. Read the 10-Q on SEC EDGAR. The figures below are from the earlier press release; the 10-Q has the full statements and notes.
The headline numbers
Amgen reported revenue of $10.4B for Q3 2026, compared with $9.6B a year earlier (+8.5%). Net income was $3.9B, compared with $3.2B (+20.1%), and diluted earnings per share were $7.08, compared with $5.93. These are GAAP figures, prepared under the standard accounting rules. How EPS is calculated.
Comparing Q3 2026 (Jul to Sep 2026) with Q3 2025 (Jul to Sep 2025)
Each pair of bars shows both periods. Longer bar, more money. Bars in a group share one scale.
Q3 2026Q3 2025
Revenue and profit (GAAP)
Per share (GAAP)
Cash flow, the first nine months (GAAP)
| Line | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $10,365M | $9,557M | +8.5% |
| Operating income | $3,710M | $2,526M | +46.9% |
| Net income | $3,864M | $3,216M | +20.1% |
| Diluted EPS | $7.08 | $5.93 | +19.4% |
Change is worked out by Ticker Sage from the two figures shown. Operating margin, operating income as a share of revenue, was 35.8% compared with 26.4%. What profit margins measure.
Cash flow
| Line | Jan to Sep 2026 | Jan to Sep 2025 | Change |
|---|---|---|---|
| Cash from operations, first nine months | $10,432M | $8,355M | +24.9% |
The release reports cash flow for the first nine months of the fiscal year, so these columns cover that longer period, not the quarter alone. How free cash flow works.
What management said
"Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise"
What to look for in the 10-Q
The press release has the headline tables. The 10-Q adds the full statements, the notes and management's discussion, including:
- Segment detail. Revenue and profit by business, and the reasons the company gives for changes.
- Items the adjusted measures leave out. Where those charges sit in the GAAP statements.
- Debt and risk factors. Any changes to borrowings and the risk factors section since the 10-K.
How an 8-K, a 10-Q and a 10-K differ. When the 10-Q is filed, the box at the top of this page links to it.
Sources
- Exhibit 99.1: press release and financial tables, filed Nov 3, 2026
- Form 8-K filing index on SEC EDGAR
- Amgen Form 10-K for fiscal 2025
Common questions
When did Amgen report Q3 2026 results?
Amgen filed its Q3 2026 press release with the SEC on Nov 3, 2026, as Exhibit 99.1 to a Form 8-K under Item 2.02 (Results of Operations and Financial Condition).
What were Amgen's revenue and EPS for Q3 2026?
Revenue was $10.4B, compared with $9.6B in Q3 2025. Diluted EPS was $7.08, compared with $5.93.
Has Amgen filed its 10-Q for Q3 2026?
Yes. Amgen filed the 10-Q on Nov 4, 2026.
Amgen company file → · Amgen filings news · Learn
Disclosures
- Editor holdings in AMGN
- The editor holds no position in Amgen (AMGN). As of Nov 11, 2026.
- Compensation
- Nobody paid for this page. No affiliate links.
- Sources
- Amgen's own SEC filings, linked next to each number.
- Last updated
- Nov 4, 2026
A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold AMGN. It reports what the company said and doesn't compare the results with forecasts by anyone else.